Literature DB >> 22479088

Stability of Ibuprofen solutions in normal saline or 5% dextrose in water.

Scott E Walker1, Julie Choudhury, Shirley Law, John Iazzetta.   

Abstract

BACKGROUND: A shortage of the standard medication for treatment of patent ductus arteriosus has necessitated use of parenteral ibuprofen, which is equally efficacious for this indication. The beyond-use date recommended by the manufacturer is very short and has implications for resource allocation and wastage.
OBJECTIVE: To evaluate the stability of ibuprofen (undiluted or diluted in either 0.9% sodium chloride [normal saline; NS] or 5% dextrose in water [D5W]) with storage for up to 21 days under refrigeration or at room temperature in glass vials or polypropylene syringes.
METHODS: Six glass vials, each containing undiluted ibuprofen (5 mg/mL), were prepared. In addition, ibuprofen was diluted to 2.5 mg/mL in NS or D5W, and 6 syringes were prepared for each diluent (total of 12 syringes). Finally, 6 extension tubes were each primed with 1 mL of ibuprofen (duplicates of undiluted solution and solutions diluted to 2.5 mg/mL in NS or D5W). Half of the vials, syringes, and tubes were stored under refrigeration (4°C) and the other half at room temperature (23°C). The concentration of ibuprofen was determined by a validated, stability-indicating liquid chromatographic method on study days 0, 1, 2, 3, 6, 8, 10, 13, 17, and 21 for samples stored in vials and syringes, or at time 0, 6, 24, and 30 h for samples stored in tubes.
RESULTS: Analysis of variance showed differences in the percentage of ibuprofen remaining due to study day (p < 0.001) and diluent (p < 0.005), but no differences due to concentration (p = 0.06) or temperature (p = 0.12). All solutions of ibuprofen were stable throughout the study period, retaining at least 90% of their initial concentration.
CONCLUSIONS: Undiluted ibuprofen (5 mg/mL) stored in glass vials and ibuprofen diluted to 2.5 mg/mL with either NS or D5W and stored in polypropylene syringes will retain more than 92% of its initial concentration with storage for up to 14 days at 4°C. A beyond-use date of 14 days would allow for up to 24 h storage at 23°C during this 14-day period. Storage of ibuprofen solutions in extension tubing should not exceed 29 h at 4°C or 17 h at 23°C. Beyond-use dates should be applied only after consideration of US Pharmacopeia Revised General Chapter <797> guidelines for compounding of sterile preparations.

Entities:  

Keywords:  drug stability; ibuprofen

Year:  2011        PMID: 22479088      PMCID: PMC3203828          DOI: 10.4212/cjhp.v64i5.1071

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  15 in total

1.  Cost effective evaluation of a stability study.

Authors:  S E Walker; Y Hanabusa; G Dranitsaris; W R Bartle; J Iazzetta
Journal:  Can J Hosp Pharm       Date:  1987-08

2.  USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy.

Authors:  Eric S Kastango; Brian D Bradshaw
Journal:  Am J Health Syst Pharm       Date:  2004-09-15       Impact factor: 2.637

3.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

4.  Sample size calculations for clinical pharmacology studies.

Authors:  P D Stolley; B L Strom
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

Review 5.  Patent ductus arteriosus of the preterm infant.

Authors:  Shannon E G Hamrick; Georg Hansmann
Journal:  Pediatrics       Date:  2010-04-26       Impact factor: 7.124

6.  A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.

Authors:  B Van Overmeire; K Smets; D Lecoutere; H Van de Broek; J Weyler; K Degroote; J P Langhendries
Journal:  N Engl J Med       Date:  2000-09-07       Impact factor: 91.245

7.  Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial.

Authors:  B-H Su; H-C Lin; H-Y Chiu; H-Y Hsieh; H-H Chen; Y-C Tsai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09-03       Impact factor: 5.747

8.  Pharmacologic closure of patent ductus arteriosus in the premature infant.

Authors:  W F Friedman; M J Hirschklau; M P Printz; P T Pitlick; S E Kirkpatrick
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

9.  The Vermont-Oxford Trials Network: very low birth weight outcomes for 1990. Investigators of the Vermont-Oxford Trials Network Database Project.

Authors: 
Journal:  Pediatrics       Date:  1993-03       Impact factor: 7.124

10.  Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.

Authors:  W M Gersony; G J Peckham; R C Ellison; O S Miettinen; A S Nadas
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

View more
  2 in total

1.  Assessment of stability of ketamine-xylazine preparations with or without acepromazine using high performance liquid chromatography-mass spectrometry.

Authors:  Aurore Dodelet-Devillers; Chiara Zullian; Pascal Vachon; Francis Beaudry
Journal:  Can J Vet Res       Date:  2016-01       Impact factor: 1.310

2.  Deep Eutectic Solvent Formulations and Alginate-Based Hydrogels as a New Partnership for the Transdermal Administration of Anti-Inflammatory Drugs.

Authors:  Sónia N Pedro; Maria S M Mendes; Bruno M Neves; Isabel Filipa Almeida; Paulo Costa; Inês Correia-Sá; Carla Vilela; Mara G Freire; Armando J D Silvestre; Carmen S R Freire
Journal:  Pharmaceutics       Date:  2022-04-10       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.